KR102754522B1 - 아데노신 수용체 길항제 및 이의 용도 - Google Patents

아데노신 수용체 길항제 및 이의 용도 Download PDF

Info

Publication number
KR102754522B1
KR102754522B1 KR1020207028522A KR20207028522A KR102754522B1 KR 102754522 B1 KR102754522 B1 KR 102754522B1 KR 1020207028522 A KR1020207028522 A KR 1020207028522A KR 20207028522 A KR20207028522 A KR 20207028522A KR 102754522 B1 KR102754522 B1 KR 102754522B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
compound
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207028522A
Other languages
English (en)
Korean (ko)
Other versions
KR20200132901A (ko
Inventor
지웬 리우
엘파티 엘제인
Original Assignee
테온 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테온 테라퓨틱스, 인크. filed Critical 테온 테라퓨틱스, 인크.
Publication of KR20200132901A publication Critical patent/KR20200132901A/ko
Application granted granted Critical
Publication of KR102754522B1 publication Critical patent/KR102754522B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020207028522A 2018-03-05 2019-03-05 아데노신 수용체 길항제 및 이의 용도 Active KR102754522B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862638737P 2018-03-05 2018-03-05
US62/638,737 2018-03-05
US201862688088P 2018-06-21 2018-06-21
US62/688,088 2018-06-21
PCT/US2019/020810 WO2019173380A1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Publications (2)

Publication Number Publication Date
KR20200132901A KR20200132901A (ko) 2020-11-25
KR102754522B1 true KR102754522B1 (ko) 2025-01-13

Family

ID=67847428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207028522A Active KR102754522B1 (ko) 2018-03-05 2019-03-05 아데노신 수용체 길항제 및 이의 용도

Country Status (12)

Country Link
US (3) US20210040097A1 (cg-RX-API-DMAC10.html)
EP (2) EP4364727A3 (cg-RX-API-DMAC10.html)
JP (3) JP7849948B2 (cg-RX-API-DMAC10.html)
KR (1) KR102754522B1 (cg-RX-API-DMAC10.html)
CN (1) CN112218867B (cg-RX-API-DMAC10.html)
AU (2) AU2019232736B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020018158A2 (cg-RX-API-DMAC10.html)
ES (1) ES2975753T3 (cg-RX-API-DMAC10.html)
IL (1) IL277144B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020009286A (cg-RX-API-DMAC10.html)
SG (1) SG11202008611UA (cg-RX-API-DMAC10.html)
WO (1) WO2019173380A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用
BR112023002180A2 (pt) * 2020-08-07 2023-05-02 Teon Therapeutics Inc Terapia de combinação com antagonistas de receptor de adenosina
EP4211135A1 (en) * 2020-09-04 2023-07-19 Teon Therapeutics, Inc. Cocrystals of an adenosine a2b receptor antagonist
TW202313612A (zh) 2021-06-04 2023-04-01 美商天恩治療有限公司 腺苷ab受體拮抗劑的固體形式
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法
EP4554943A1 (en) * 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
EP1075472A1 (en) * 1998-04-15 2001-02-14 Warner-Lambert Company Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
GEP20074230B (en) * 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
WO2004106337A1 (en) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
PL1789053T3 (pl) * 2004-09-01 2012-12-31 Gilead Sciences Inc Sposób gojenia się rany wykorzystujący antagonistów receptora adenozynowego A2B
EP2311462A1 (en) 2004-10-15 2011-04-20 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
CA2612344A1 (en) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
CA2646333C (en) 2006-03-17 2014-06-17 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
WO2008066627A2 (en) 2006-10-24 2008-06-05 Board Of Regents, The University Of Texas System Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction
WO2009088518A1 (en) 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
WO2009157938A1 (en) 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
NZ604423A (en) * 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR20130088834A (ko) 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 a2b 아데노신 수용체 길항제의 용도
EP2616470B1 (en) * 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012170209A2 (en) * 2011-05-23 2012-12-13 Nectid, Inc. Benzofuran-2 carboxamide compounds
US10117868B2 (en) 2011-10-25 2018-11-06 Case Western Reserve University Systems pharmacology for treating ocular disorders
US10702476B2 (en) 2017-08-14 2020-07-07 Phosphorex, Inc. Microparticle formulations of adenosine receptor antagonists for treating cancer
KR20200103018A (ko) 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
JP7849948B2 (ja) 2018-03-05 2026-04-22 テオン セラピューティクス,インク. アデノシン受容体アンタゴニストおよびその使用

Also Published As

Publication number Publication date
US20210163483A1 (en) 2021-06-03
EP4364727A2 (en) 2024-05-08
IL277144B1 (en) 2024-02-01
JP2024032976A (ja) 2024-03-12
CA3093234A1 (en) 2019-09-12
KR20200132901A (ko) 2020-11-25
EP4364727A3 (en) 2024-05-15
US11124515B2 (en) 2021-09-21
AU2024204483B2 (en) 2026-04-02
ES2975753T3 (es) 2024-07-12
IL277144B2 (en) 2024-06-01
AU2019232736B2 (en) 2024-05-02
US20220056033A1 (en) 2022-02-24
SG11202008611UA (en) 2020-10-29
US20210040097A1 (en) 2021-02-11
EP3762386B1 (en) 2024-01-24
EP3762386A1 (en) 2021-01-13
AU2024204483A1 (en) 2024-07-18
CN112218867B (zh) 2023-11-21
JP2026074199A (ja) 2026-05-01
IL277144A (en) 2020-10-29
CN112218867A (zh) 2021-01-12
BR112020018158A2 (pt) 2021-02-02
AU2019232736A1 (en) 2020-10-08
JP2021517164A (ja) 2021-07-15
WO2019173380A1 (en) 2019-09-12
JP7849948B2 (ja) 2026-04-22
EP3762386A4 (en) 2021-11-24
MX2020009286A (es) 2020-12-11

Similar Documents

Publication Publication Date Title
EP3762386B1 (en) Adenosine receptor antagonists and uses thereof
TWI856956B (zh) 人類整合素α4β7拮抗劑
JP6602902B2 (ja) 脾臓チロシンキナーゼi(syk)阻害剤としての2−(2−アミノシクロヘキシル)アミノピリミジン−5−カルボキサミド類
TWI473613B (zh) 用作肥大細胞類胰蛋白酶抑制劑之〔4-(5-胺基甲基-2-氟-苯基)-六氫吡啶-1-基〕-〔7-氟-1-(2-甲氧基-乙基)-4-三氟甲氧基-1h-吲哚-3-基〕-甲酮
WO2021000054A1 (en) Cannabinoid derivatives
CN100508975C (zh) 吡唑并吡啶化合物的用途
JPS6338026B2 (cg-RX-API-DMAC10.html)
CH679583A5 (cg-RX-API-DMAC10.html)
HK40108164A (en) Adenosine receptor antagonists and uses thereof
HK40041747A (en) Adenosine receptor antagonists and uses thereof
HK40041747B (en) Adenosine receptor antagonists and uses thereof
CA3093234C (en) Adenosine receptor antagonists and uses thereof
EA043897B1 (ru) Антагонисты аденозиновых рецепторов и их применения
JP2021532069A (ja) 新規な気管支拡張性ヘテロ結合アミド
JP2730135B2 (ja) 酸アミド誘導体
WO2016019847A1 (zh) 一种氟代达比加群酯衍生物及其制备方法和在药学上的用途
JP5983714B2 (ja) 含フッ素アミノ酸プロドラッグの結晶形とその製造方法
WO2025096782A1 (en) Fluorinated cannabinoid compositions and methods thereof
JPS642596B2 (cg-RX-API-DMAC10.html)
JP2025518969A (ja) イミダゾリジニルバニリン酸エーテル誘導体およびその使

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201005

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220304

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240422

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241217

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250109

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250109

End annual number: 3

Start annual number: 1

PG1601 Publication of registration